➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
Baxter
McKinsey
Harvard Business School

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

HALOPERIDOL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Haloperidol, and when can generic versions of Haloperidol launch?

Haloperidol is a drug marketed by Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, SCS, Teva, Teva Pharms, Abraxis Pharm, Akorn, Baxter Hlthcare Corp, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, West-ward Pharms Int, Appco, Cycle Pharms Ltd, Duramed Pharms Barr, Innogenix, Lederle, Mylan, Par Pharm, Purepac Pharm, Quantum Pharmics, Royce Labs, Sandoz, Vintage, Zydus Pharms Usa, Hospira, Sandoz Inc, Somerset Theraps Llc, Zydus Pharms, Hikma, and Actavis Mid Atlantic. and is included in one hundred and five NDAs.

The generic ingredient in HALOPERIDOL is haloperidol decanoate. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.

US ANDA Litigation and Generic Entry Outlook for Haloperidol

A generic version of HALOPERIDOL was approved as haloperidol decanoate by FRESENIUS KABI USA on December 19th, 1997.

  Start Trial

Drug patent expirations by year for HALOPERIDOL
Drug Prices for HALOPERIDOL

See drug prices for HALOPERIDOL

Drug Sales Revenue Trends for HALOPERIDOL

See drug sales revenues for HALOPERIDOL

Recent Clinical Trials for HALOPERIDOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Canadian Institutes of Health Research (CIHR)Phase 4
University of CalgaryPhase 4
Services Institute of Medical Sciences, PakistanPhase 1

See all HALOPERIDOL clinical trials

Pharmacology for HALOPERIDOL
Medical Subject Heading (MeSH) Categories for HALOPERIDOL

US Patents and Regulatory Information for HALOPERIDOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purepac Pharm HALOPERIDOL haloperidol TABLET;ORAL 071076-001 Aug 4, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs HALOPERIDOL haloperidol TABLET;ORAL 071571-001 Jun 3, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Cycle Pharms Ltd HALOPERIDOL haloperidol TABLET;ORAL 071133-001 May 12, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Appco HALOPERIDOL haloperidol TABLET;ORAL 211061-003 Jan 8, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
Baxter
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.